Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT02938494 Completed - Acne Vulgaris Clinical Trials

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Start date: November 2015
Phase: Phase 2
Study type: Interventional

Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris

NCT ID: NCT02935036 Completed - Acne Vulgaris Clinical Trials

Efficacy Study in Patients With Acne Vulgaris.

Start date: October 3, 2016
Phase: Phase 2
Study type: Interventional

Safety and efficacy study in patients with acne vulgaris

NCT ID: NCT02932306 Completed - Acne Clinical Trials

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Start date: November 3, 2015
Phase: Phase 3
Study type: Interventional

The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score [EGSS] of 3 [moderate] or 4 [severe]).

NCT ID: NCT02932267 Completed - Acne Vulgaris Clinical Trials

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

EDeN
Start date: February 2, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face. All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump Forte) once daily on whole face. The purpose of this trial is to evaluate subject reported outcomes with the combination of Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (IV to VI).

NCT ID: NCT02929719 Completed - Acne Vulgaris Clinical Trials

Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Start date: April 2014
Phase: Phase 1
Study type: Interventional

Therapeutic equivalence and safety study

NCT ID: NCT02913001 Completed - Acne Vulgaris Clinical Trials

The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne

Start date: September 2014
Phase: N/A
Study type: Interventional

This randomized controlled trial will examine changes in some hormonal markers associated with acne among adults with moderate/severe acne randomized to a low glycemic index and glycemic load diet or usual eating plan for two weeks.

NCT ID: NCT02905851 Completed - Acne Vulgaris Clinical Trials

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

Start date: May 2016
Phase: N/A
Study type: Interventional

To see if teledermatology can be used to reduce antibiotic burden in patients on doxycycline or minocycline for acne vulgaris

NCT ID: NCT02899000 Completed - Acne Vulgaris Clinical Trials

A Treatment for Severe Inflammatory Acne Subjects

Start date: July 29, 2016
Phase: Phase 4
Study type: Interventional

Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.

NCT ID: NCT02886715 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Start date: September 21, 2016
Phase: Phase 3
Study type: Interventional

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

NCT ID: NCT02865005 Completed - Acne Vulgaris Clinical Trials

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

Start date: February 2016
Phase: Phase 3
Study type: Interventional

Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.